Meropenem
Meropenem Sodium — Group 2 Antipseudomonal Carbapenem Antibiotic
🧬 Mechanism of Action & Target Pathway
Penicillin-Binding Protein (PBP) Inactivation
- Penetrates Gram-negative outer membrane via OprD porin channels.
- Binds with high affinity to essential PBPs (PBPs 2, 3, and 4) in cell wall synthesis.
- Inhibits peptidoglycan cross-linking transpeptidation.
- Resistant to most beta-lactamases (TEM, SHV, CTX-M ESBLs, and AmpC enzymes).
- Induces rapid cell wall destruction and bactericidal lysis.
Antimicrobial Spectrum & Coverage Framework — Meropenem
Educational ReferenceGram-Positive Organisms
Covered:
- ✓ Methicillin-susceptible Staphylococcus aureus (MSSA)
- ✓ Streptococcus pneumoniae
- ✓ Streptococcus pyogenes
- ✓ Enterococcus faecalis (variable/intermediate)
Not Covered:
- ✕ Methicillin-resistant Staphylococcus aureus (MRSA)
- ✕ Enterococcus faecium
- ✕ Listeria monocytogenes
Gram-Negative Organisms
Covered:
- ✓ Pseudomonas aeruginosa
- ✓ ESBL-producing Escherichia coli
- ✓ ESBL-producing Klebsiella pneumoniae
- ✓ AmpC Enterobacter cloacae
- ✓ Citrobacter freundii
- ✓ Acinetobacter baumannii (susceptible)
- ✓ Haemophilus influenzae
Not Covered:
- ✕ Stenotrophomonas maltophilia
- ✕ Burkholderia cepacia
- ✕ Carbapenemase producers (KPC, NDM, OXA-48)
Anaerobes & Special Pathogens
Covered:
- ✓ Bacteroides fragilis
- ✓ Bacteroides thetaiotaomicron
- ✓ Peptostreptococcus spp.
- ✓ Fusobacterium spp.
Not Covered:
- ✕ Clostridioides difficile
High-Yield Exam & Clinical Gaps
Pharmacokinetics & Pharmacodynamics (PK/PD) — Meropenem
time dependent⚖️ ICU Clinical Reasoning
Why I Choose It (Indications & Strengths)
- ✓Preferred therapy for invasive ESBL-producing Enterobacterales infections such as bloodstream infection, particularly in critical illness; MERINO supports carbapenem preference over piperacillin-tazobactam for ESBL/ceftriaxone-resistant E. coli or K. pneumoniae bacteremia.
- ✓A broad antipseudomonal carbapenem option when resistance risk, prior microbiology, illness severity, or infection source justifies carbapenem coverage; it should not be the automatic empiric choice when narrower active beta-lactams are appropriate.
- ✓High CSF penetration at 2.0 g IV every 8 hours for post-neurosurgical meningitis.
Why I Don't (Limitations & Gaps)
- ✕Inactivated by carbapenemases (KPC, NDM, VIM, OXA-48).
- ✕Drives carbapenem resistance (OprD porin loss in Pseudomonas aeruginosa).
- ✕Reduces serum valproic acid levels by 60–90%, triggering breakthrough seizures.
💉 Dosing & Administration Protocols
Severe Infections / Septic Shock: 1.0 g IV every 8 hours (extended 3-hour infusion preferred).
Syndrome-Specific Regimens
1.0 g IV every 8 hours (extended 3-hour infusion).
Note: MERINO failed to demonstrate noninferiority of piperacillin-tazobactam to meropenem for ceftriaxone-resistant E. coli/K. pneumoniae bloodstream infection and supports carbapenem preference for invasive ESBL-E infection; avoid describing the trial as proving a universal mortality benefit in every ESBL syndrome.
2.0 g IV every 8 hours (infused over 3 hours).
1.0 g IV every 8 hours is the adult meropenem regimen listed in the 2016 ATS/IDSA HAP/VAP guideline when meropenem is selected. Higher-dose/prolonged-infusion strategies (for example 2 g q8h) may be used for selected resistant organisms, higher MICs or altered PK according to current susceptibility/PK-PD guidance, but should not be taught as the universal VAP dose.
Renal Function Dosing
| CrCl Range | Dose Adjustment |
|---|---|
| CrCl > 50 mL/min | 1.0 g IV every 8 hours. |
| CrCl 26–50 mL/min | 1.0 g IV every 12 hours. |
| CrCl 10–25 mL/min | 500 mg IV every 12 hours. |
| CrCl < 10 mL/min | 500 mg IV every 24 hours. |
Dialytic Clearance (HD / CRRT)
🩺 Organ Failure Considerations
Cleared primarily by glomerular filtration. Mandatory dose reduction in renal impairment to avoid neurotoxicity/seizures.
Minimal hepatic metabolism; no dose reduction required in isolated liver failure.
⚠️ Toxicity & Safety Warnings
Major Warnings
- 🚨Seizures & Neurotoxicity: Seizure risk (0.5% in general, higher in renal failure or pre-existing CNS disease).
- 🚨Valproic Acid Interaction: Severe drop in valproate levels within 24 hours.
- 🚨Clostridioides difficile Colitis risk.
🔄 Bedside Drug Interactions
| Interacting Drug | Mechanism | Clinical Consequence | Mandatory ICU Action |
|---|---|---|---|
| Valproic Acid / Divalproex Sodium | Inhibition of acyl-glucuronide valproate hydrolysis and clearance acceleration | Rapid 60-90% reduction in valproate levels leading to status epilepticus | Avoid co-administration; use alternative antiepileptic. |
| Probenecid | Inhibition of tubular secretion | Increases meropenem half-life and exposure | Co-administration not recommended. |
📊 Monitoring & TDM Protocols
Required Monitoring Parameters
- ▪ Calculated CrCl and serum creatinine daily for dose adjustment
- ▪ Neurologic assessment for seizure activity or encephalopathy
- ▪ Valproic acid level if co-administered
- ▪ Clinical response and body temperature
Antimicrobial Stewardship — Broader ≠ Better (Meropenem)
De-escalate from Meropenem to narrow-spectrum agents (e.g. Cefazolin, Ampicillin-Sulbactam, or Ertapenem) as soon as culture susceptibilities permit.
Reserving Meropenem for documented ESBL or MDR Pseudomonas infections limits selection pressure for KPC carbapenemases and Metallo-beta-lactamases.
Evidence Status
CurrentLast Medically Reviewed
2026-09-11
Evidence Checked Through
2026-09-11
📚 Evidence Traceability & Guideline Citations
"The MERINO trial did not demonstrate noninferiority of piperacillin-tazobactam to meropenem for ceftriaxone-resistant E. coli/K. pneumoniae bloodstream infection; the mortality direction favored meropenem and supports carbapenem preference for invasive ESBL-E infection."
"IDSA 2026 AMR Guidance recommends Meropenem as first-line therapy for ESBL-producing Enterobacterales bloodstream infections."
🩺 Bedside Patient Scenarios
ESBL E. coli Septic Shock from Pyelonephritis
Scenario: A 65-year-old in septic shock; blood cultures grow ESBL E. coli (ceftriaxone resistant).
Rationale: A carbapenem is preferred for invasive ESBL-E infection; meropenem is favored over ertapenem in critical illness or hypoalbuminemia. MERINO supports this preference for bloodstream infection but does not make one meropenem regimen a universal gold standard for every ESBL syndrome.
Empiric Coverage in Septic Shock with History of ESBL
Scenario: Patient with known ESBL colonization presents with intra-abdominal septic shock.
Rationale: Covers potential ESBL pathogens and Pseudomonas while providing full anaerobic coverage.
🎯 Exam Traps & Board Misconceptions
Even if automated susceptibilities report Pip-Tazo susceptible, high inoculum effects lead to clinical failure. Meropenem remains the preferred choice.
Continue Learning
Ventilator-Associated Pneumonia (VAP)
Quantitative lower tract sampling (ETA vs BAL), rapid multiplex PCR panels and stewardship interpretation, PK/PD extended beta-lactams, 7-day duration, and the SHEA prevention bundle.
Hospital-Acquired Pneumonia (HAP)
Nosocomial pneumonia developing ≥ 48 hours after admission in non-ventilated patients, host and antibiogram MDR risk tailoring, nasal MRSA PCR screening, and 7-day de-escalation.
Ventilator-Associated Pneumonia Due to DTR Pseudomonas
Susceptibility-directed treatment with newer antipseudomonal beta-lactams
Invasive Candidemia in the Critically Ill
Early echinocandin therapy, source control, clearance cultures, and selective metastatic-focus evaluation
New Tachycardia & Tachyarrhythmias
Algorithmic triage of acute heart rates > 100–150 bpm: stability screen (immediate cardioversion if unstable), narrow vs wide QRS differentiation, Brugada VT rules, and sinus tachycardia etiology search.
Acute Altered Mental Status & ICU Delirium
Systematic neurologic evaluation: immediate metabolic/toxic screening (glucose, hypoxia, hypercapnia), nonconvulsive status epilepticus exclusion, structural CT triage, and CAM-ICU delirium management.